Ruxolitinib in Seborrheic Dermatitis
Part of paid clinical trials in New York, New York.
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Study ID
- NCT05787860
- Phase
- PHASE2
- Status
- Completed
Conditions
- Seborrheic Dermatitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Ruxolitinib 1.5% Cream — DRUGtopical ruxolitinib 1.5% cream twice daily for 4 weeks
Study Details
This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in healthy control subjects.
Key Dates
- Start date
- Nov 15, 2022
- Status verified
- May 2025
- Primary completion
- Jan 26, 2024
- Completion
- Jan 26, 2024
Study Design
- Enrollment
- 45 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Ruxolitinib CreamParticipants will receive topical ruxolitinib 1.5% cream
- No Intervention: Healthy Control SubjectsAge- and gender-matched healthy control subjects
Primary Outcome Measure
Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4 [ Time Frame: At end of Treatment, Week 4 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | - |
Find similar trials in New York, NY
By research site
Related Studies
- The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic DermatitisRecruiting · Integrative Skin Science and Research · Sacramento, California